|
|
Active Org.- |
|
Active Indication- |
|
Drug Highest PhaseDiscontinued |
First Approval Ctry. / Loc.- |
First Approval Date- |
注射用地西他滨不同给药剂量/方案治疗骨髓增生异常综合征(MDS)有效性和安全性的开放、多中心Ⅳ期临床研究
[Translation] An open-label, multi-center phase IV clinical study on the efficacy and safety of decitabine for injection with different doses/schemes in the treatment of myelodysplastic syndrome (MDS)
评价连云港杰瑞药业有限公司生产的注射用地西他滨(50mg)在不同给药剂量/方案下,治疗骨髓增生异常综合征 (MDS)的有效性和安全性,为优化临床给药方案提供依据。
[Translation] To evaluate the efficacy and safety of decitabine for injection (50mg) produced by Lianyungang Jereh Pharmaceutical Co., Ltd. in the treatment of myelodysplastic syndromes (MDS) at different dosages/schemes, and provide suggestions for optimizing clinical dosage regimens. in accordance with.
100 Clinical Results associated with Jari Pharmaceutical Co Ltd
0 Patents (Medical) associated with Jari Pharmaceutical Co Ltd
100 Deals associated with Jari Pharmaceutical Co Ltd
100 Translational Medicine associated with Jari Pharmaceutical Co Ltd